Results 121 to 130 of about 83,797 (191)

Dilated cardiomyopathy evaluation with Imagenomics: combining multimodal cardiovascular imaging and genetics

open access: yesESC Heart Failure, EarlyView.
Systematic approach to dilated cardiomyopathy diagnosis. Dilated cardiomyopathy is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic disfunction unexplained by abnormal loading conditions or coronary artery disease.
Kristian Galanti   +14 more
wiley   +1 more source

Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real‐world data analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims and Background Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression.
Julia Vogel   +7 more
wiley   +1 more source

The effects of early exercise on cardiovascular biomarkers in patients with congestive heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Background Exercise training improves functional outcomes in chronic heart failure (HF), but the effects of early in‐hospital physical activity on cardiovascular biomarkers and prognosis in acute congestive heart failure (AHF) patients remain unclear.
Yanxiang Sun   +6 more
wiley   +1 more source

METAB‐HTX: prospective, longitudinal cohort study evaluating cardiac and systemic metabolism after heart transplantation

open access: yesESC Heart Failure, EarlyView.
The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...
Amin Polzin   +21 more
wiley   +1 more source

The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Proposed algorithm to screen for transthyretin cardiac amyloidosis (ATTR‐CA). AL‐CA, immunoglobulin light‐chain cardiac amyloidosis; AMYLI, AMYLoidosis Index; AUC, area under the curve; IWT, increased wall thickness; LVEF, left ventricular ejection fraction; PYP, pyrophosphate.
Giovanni Battista Bonfioli   +11 more
wiley   +1 more source

Pantethine therapy dramatically rescues end‐stage failing heart in a patient with deficiency of coenzyme A biosynthesis

open access: yes
ESC Heart Failure, EarlyView.
Violette Goetz   +9 more
wiley   +1 more source

Microvascular obstruction in cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Cardiac amyloidosis (CA) is characterized by deposition of amyloid fibrils within the extracellular space, causing disarray of the myocardial structure and capillary architecture. This study aims to characterize the prevalence of microvascular obstruction (MVO) in patients with CA and to assess the association between MVO and prognosis ...
Lucrezia Netti   +19 more
wiley   +1 more source

New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T and NT‐proBNP

open access: yesEuropean Journal of Heart Failure, EarlyView.
(A) Univariable receiver operating characteristic (ROC) curves for all biomarkers. (B) Kaplan–Meier curves for best cut‐point of mid‐regional pro‐adrenomedullin (MR‐proADM) for survival (n = 442). AUC, area under the curve; CI, confidence interval; HR, hazard ratio; hsTnT, high‐sensitivity troponin T; MR‐proANP, mid‐regional pro‐atrial natriuretic ...
Markus S. Anker   +18 more
wiley   +1 more source

Current and novel biomarkers in cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy